Keyword: Dupixent

Amid a restructuring of its partnership with Sanofi for Praluent and Kevzara, Regeneron is planning to lay off 15 New York staffers.

Dupixent's number-one position in the eczema market will be tough to maintain as two dozen rivals line up to unseat it, Cantor Fitzgerald warns.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.

Sanofi and Regeneron recently debuted an unbranded awareness and education campaign around type 2 inflammation and its connections across conditions.

Dupixent is on track to deliver about €2 billion in annual sales, but Sanofi execs say they're still in early stages of the launch.

As Pfizer advances a phase 3 rival to Regeneron and Sanofi's Dupixent, one analyst says it'll struggle to steal share because of side effects.

GlaxoSmithKline's Nucala has been on the prowl for a leg up in severe asthma. Could new real-world data work some magic for the drug?

Regeneron has lost its edge in antibody development, so its growth potential may be limited, Analysts at SVBLeerink argue in a new report.

Eli Lilly and Incyte's Olumiant has run up against safety hurdles in the past. But can they stop the drugmakers from adding another indication?